Altravax
Stage
Grant - II | AliveTotal Raised
$4.65MLast Raised
$3.45M | 10 yrs agoAbout Altravax
Altravax is a biopharmaceutical company that has acquired the rights to MolecularBreeding directed molecular evolution technology in the area of infectious diseases. The company is focused on the discovery and development of new vaccines to fight infectious diseases. Altravax's technologies offer opportunities to create vaccines or improve currently available alternatives to fill unmet medical needs. The company has a robust pipeline of candidates at various stages of development. Altravax also seeks to partner with other companies and organizations to develop vaccines which meet defined healthcare and market criteria.
Missing: Altravax's Product Demo & Case Studies
Promote your product offering to tech buyers.
Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.
Missing: Altravax's Product & Differentiators
Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).
Expert Collections containing Altravax
Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.
Altravax is included in 1 Expert Collection, including Biopharma Tech.
Biopharma Tech
1,568 items
Altravax Patents
Altravax has filed 7 patents.
Application Date | Grant Date | Title | Related Topics | Status |
|---|---|---|---|---|
3/12/2014 | 5/31/2016 | Vaccines, Vaccination, Virology, Antivirals, Infectious causes of cancer | Grant |
Application Date | 3/12/2014 |
|---|---|
Grant Date | 5/31/2016 |
Title | |
Related Topics | Vaccines, Vaccination, Virology, Antivirals, Infectious causes of cancer |
Status | Grant |
Latest Altravax News
Feb 9, 2017
Western Equine Encephalitis - Pipeline Review, H2 2016 - Key Players are Akshaya Bio, Altravax, EpiVax, H&P Labs & Profectus BioSciences - Research and Markets February 09, 2017 09:43 AM Eastern Standard Time DUBLIN--( BUSINESS WIRE )--Research and Markets has announced the addition of the "Western Equine Encephalitis - Pipeline Review, H2 2016" report to their offering. Western equine encephalitis is a disease that is spread to humans by infected mosquitoes. Western equine encephalitis is caused by the western equine encephalitis virus, an arbovirus. Symptoms range from mild to severe and may include only fever and headache to encephalitis with delirium, disorientation or coma. This report provides comprehensive information on the therapeutic development for Western Equine Encephalitis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Western Equine Encephalitis and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered:
Altravax Frequently Asked Questions (FAQ)
Where is Altravax's headquarters?
Altravax's headquarters is located at 102 Broadway N, Fargo.
What is Altravax's latest funding round?
Altravax's latest funding round is Grant - II.
How much did Altravax raise?
Altravax raised a total of $4.65M.
Who are the investors of Altravax?
Investors of Altravax include National Institute of Allergy and Infectious Diseases.
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.